C1904931-4
IPOS

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: C07D 409/12, A61K 31/535, 31/38 — A1

(11) International Publication Number: WO 98/45288

(43) International Publication Date: 15 October 1998 (15.10.98)

(21) International Application Number: PCT/US98/07274

(22) International Filing Date: 7 April 1998 (07.04.98)

(30) Priority Data:
60/043,223 9 April 1997 (09.04.97) US

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).


(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: NEUBAUER, Blake, Lee [US/US]; 6943 Central Avenue, Indianapolis, IN 46220–1025 (US).

(74) Agents: BOUDREAUX, William, R. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: TREATMENT OR PROPHYLAXIS OF PROSTATIC CANCER AND BENIGN PROSTATIC HYPERPLASIA WITH SELECTIVE ESTROGEN RECEPTOR MODULATORS



(I)

(57) Abstract

The present invention provides a method for the treatment or prophylaxis of benign prostatic hyperplasia or prostatic cancer in a patient in need of such treatment comprising administering a selective estrogen receptor modulating compound of formula (I), in which R^1 and R^2 are independently hydroxy and alkoxy of one to four carbon atoms; and R^3 and R^4 are independently methyl or ethyl, or R^3 and R^4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl–pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.